AMAZING PRAGUE (PRAGUE-12) (AmP)
Surgical Treatment of Atrial Fibrillation - Prospective Randomized Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Pilsen, Czech Republic, 305 99
- Cardiosurgery Department of University Hospital in Pilsen
-
Prague, Czech Republic, 10034
- Cardiocentre of Kralovske Vinohrady University Hospital
-
Usti nad Labem, Czech Republic, 40113
- Cardiology department of Masarykova Hospital Usti nad Labem
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- indication to a cardiac surgery (coronary bypass, valve repair, others or combination of those)
- atrial fibrillation (paroxysmal, persistent or permanent) present or documented in last 6 month before the operation
- signed informed consent
Exclusion Criteria:
- rejection of signing the informed consent with randomization
- emergent surgery
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
A = MAZE
Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation together with MAZE procedure
|
Maze procedure according to standards of the department
|
|
B = non-MAZE
Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation (without MAZE procedure).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
presence of sinus rhythm
Time Frame: 1 year after surgery
|
1 year after surgery
|
|
death, myocardial infarction, vascular cerebral attack, renal failure with a need of haemodyalisis
Time Frame: 30 postoperative days
|
30 postoperative days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
mortality, presence of sinus rhythm, serious complications- bleeding, vascular cerebral attack, heart failure, anticoagulation, anti-arrhytmics, pacemaker or ICD implantation, catether ablation...
Time Frame: 1,3,5 months 1,5 years after surgery
|
1,3,5 months 1,5 years after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zbynek Straka, Prof.,MUDr.,CSc., Charles University, Prague
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 121402
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.